No More Sarepta-Like Development, FDA Officials Say
OND Director Jenkins says Sarepta's Exondys 51 shouldn't be a model, gets an earful from patient advocates.
OND Director Jenkins says Sarepta's Exondys 51 shouldn't be a model, gets an earful from patient advocates.